Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.
Lakshmi SandhyaNirmala Devi SreenivasanLuxitaa GoenkaBiswajit DubashiSmita KayalManikandan SolaiappanRamkumar GovindarajalouHarichandrakumar KtPrasanth GanesanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Low-dose, daily olanzapine is a simple, inexpensive, well-tolerated intervention that significantly improves appetite and weight gain in newly diagnosed patients on chemotherapy.
Keyphrases
- newly diagnosed
- double blind
- locally advanced
- weight gain
- placebo controlled
- squamous cell carcinoma
- low dose
- rectal cancer
- body mass index
- clinical trial
- chemotherapy induced
- end stage renal disease
- neoadjuvant chemotherapy
- randomized controlled trial
- weight loss
- small cell lung cancer
- radiation therapy
- phase iii
- birth weight
- phase ii study
- ejection fraction
- phase ii
- physical activity
- study protocol
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- body weight
- drug induced